IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene TOP2A Ensembl ENSG00000131747 Chromosome 17 Start 35798321 End 35827934
Description TOP2A_HUMAN Isoform 2 of P11388 - Homo sapiens (Human) [Source:UniprotKB/SpliceVariant;Acc:P11388-2]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :
     HGNC : 11989
     Entrez Gene : 7153
     UCSC : uc002huq.2
     GeneCards : 11989
     RefSeq : NM_001067
     CCDS : CCDS45672.1
     Uniprot : Q9UQP9
     Interpro : Q9UQP9
     OMIM : 126430
     GeneTests : TOP2A
     CGAP : TOP2A

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1592_at  1.64  2.63e-17  1.16e-15  2.46  3.83e-15  1.23e-13
 HG_U95  40145_at  2.24  1.49e-23  1.60e-21  3.11  1.16e-15  4.28e-14
 HG_U95  904_s_at  1.71  4.48e-19  2.67e-17  2.39  1.29e-14  3.80e-13
 HG_U133A  201291_s_at  3.39  4.55e-62  4.17e-60  7.11  3.44e-110  3.10e-109
 HG_U133A  201292_at  2.70  2.95e-67  3.46e-65  3.69  1.44e-96  8.90e-96
 HG_U133_Plus2  201291_s_at  2.80  3.08e-36  4.24e-34  3.30  1.07e-33  7.71e-32
 HG_U133_Plus2  201292_at  2.66  1.39e-43  4.48e-41  3.45  2.20e-45  1.11e-42
 HG_U133_Plus2  237469_at  1.60  3.19e-11  2.70e-10  1.58  1.44e-9  6.06e-9
 Stanford  4490  2.25  4.65e-8  1.50e-5  2.80  6.69e-9  3.37e-6
 Stanford  5388  1.06  1.35e-3  1.77e-2  1.47  1.10e-4  2.95e-3
 Stanford  21326  2.29  1.47e-8  6.94e-6  2.56  5.58e-8  1.36e-5
 Stanford  23474  1.06  1.35e-3  1.77e-2  1.47  1.10e-4  2.95e-3
 Agilent_HS_21.6K  8333  0.60  1.28e-7  4.12e-6  0.85  2.10e-11  1.51e-9

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  201291_s_at  0.15  8.49e-1  9.88e-1  0.36  3.04e-1  1.00e+0
 HG_U133A  201292_at  0.20  7.47e-1  9.74e-1  0.27  2.89e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1592_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 40145_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 904_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 201291_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 201292_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 201291_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 201292_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 237469_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 4490    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 5388    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 21326    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 23474    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 8333    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
top2a cancer Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated. 14632727 Human
top2a tumours TOP2A gene is located adjacent to the HER-2 oncogene at the chromosome location 17q12-q21 and is either amplified or deleted, with equal frequency, in almost 90% of HER-2 amplified primary breast tumours. 14632727 Human
top2a tumours In this issue of the Cytopathology, Bofin et al. present preliminary evidence for high prevalance of TOP2A amplification and deletion not only in the HER-2 amplified breast tumours, but also in the primary breast tumours without the HER-2 amplification. 14632727 Human
top2a cancer This finding together with the concept that TOP2A gene amplification and deletion seem to account for both relative chemosensitivity and resistance to topoII-inhibitor therapy further highlights the importance of screening for TOP2A gene copy number aberr 14632727 Human
top2a breast carcinomas TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. 14632728 Human
top2a breast carcinoma Using fluorescence in situ hybridization (FISH), we have examined fine needle aspiration smears from 42 cases of breast carcinoma with probes for TOP2A, HER-2 and chromosome 17. 14632728 Human
top2a breast cancer We found that amplification of TOP2A is a frequent finding in breast cancer and is often but not exclusively accompanied by HER-2 gene amplification. 14632728 Human
top2a breast cancer Testing for TOP2A aberrations may be useful in the search for individually tailored treatment regimes for breast cancer. 14632728 Human
top2a tumours Fourteen of 588 genes tested displayed specific up-regulation (CCND2, PCNA, N-MYC, E2F3, TOP2A, PAK1, DCC and PCDH2) or down-regulation (VEGF, IGFBP5, TIMP3, ARHB, C-FOS and CD9) in the pool of tumours with decreased exon 5 +/- ratio. 12165855 Human
top2a tumour In tumour samples, as compared to normal lung tissue, the up-regulated genes included such known tumour markers as CCNB1, PLK, tenascin, KRT8, KRT19 and TOP2A. 12173052 Human
top2a breast tumor Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. 14978790 Human
top2a tumors It has been proposed that the HER2 gene amplification reported in these tumors might mask an underlying TOP2A gene amplification that occurs frequently and concurrently with HER2 amplification. 14978790 Human
top2a breast cancer Topoisomerase II alpha, encoded by TOP2A, is a direct molecular target of anthracycline drug action and is potentially useful as a predictive marker of response to anthracycline therapy for breast cancer. 14978790 Human
top2a breast tumors In this study, we examined whether TOP2A gene amplification is an appropriate marker for identifying breast tumors expressing high levels of topoisomerase II alpha. 14978790 NA
top2a breast tumors We determined topoisomerase II alpha protein expression by immunohistochemistry in 81 human breast tumors in relation to HER2 and TOP2A gene copy numbers analyzed by fluorescence in situ hybridization, histologic grade, cell proliferation fraction measure 14978790 Human
top2a breast cancer Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. 15068318 Human
top2a tumours Sixteen (80%) of these carcinomas were in the HercepTest 3+ group, but four tumours had alterations in the TOP2A gene with normal HER2 status. 15068318 Human
top2a carcinomas Sixteen (80%) of these carcinomas were in the HercepTest 3+ group, but four tumours had alterations in the TOP2A gene with normal HER2 status. 15068318 Human
top2a gastric cancer In our study, we characterized the amplification (52 cases) and expression (29 cases) levels of ERBB2, TOP2A and DARPP32 in gastric cancer samples. 14991576 Human
top2a myelodysplastic syndrome Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia. 11425459 Human
top2a acute myeloid leukemia Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia. 11425459 Human
top2a tumor The median copy number of ERBB2, RARA, and TOP2A genes in the tumor cells was six (range: 4--10). 11425459 Human
top2 mixed-lineage leukemia (mll) VP-16 (etoposide) has recently been shown to induce topoisomerase II (TOP2)-mediated DNA cleavage within the mixed lineage leukemia (MLL) breakpoint cluster region (bcr), suggesting a role of TOP2 in MLL gene rearrangement. 11406628 Human
top2a lung cancer A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. 10699927 Human
top2 leukemias Topoisomerase II (top2) has been implicated in the initial steps of chromosomal translocations leading to leukemias and lymphomas, since it can generate DNA cleavage. 10954596 Human
top2 lymphomas Topoisomerase II (top2) has been implicated in the initial steps of chromosomal translocations leading to leukemias and lymphomas, since it can generate DNA cleavage. 10954596 Human
top2 cancer DNA topoisomerase II (top2) is a nuclear enzyme which resolves the topological constraints during DNA metabolism and is the target of some of the most active drugs used in cancer chemotherapy. 10652607 Human
top2a urinary bladder cancer HER-2 and TOP2A coamplification in urinary bladder cancer. 14566826 Human
top2a breast cancer In breast cancer, the adjacent TOP2A gene, the molecular target for several anticancer drugs, is frequently coamplified together with HER-2. 14566826 Human
top2a bladder cancer To study the amplification and expression of TOP2A and HER-2 and associations with tumor phenotype and clinical outcome in bladder cancer, a tissue microarray containing 2,317 bladder tumor samples was analyzed by FISH and immunohistochemistry. 14566826 Human
top2a tumor To study the amplification and expression of TOP2A and HER-2 and associations with tumor phenotype and clinical outcome in bladder cancer, a tissue microarray containing 2,317 bladder tumor samples was analyzed by FISH and immunohistochemistry. 14566826 Human
top2a tumors Amplifications were most frequently seen in advanced-stage (pT2-4) tumors (HER-2 13.8%, TOP2A 3.4%). 14566826 Human
top2a tumors Of HER-2-amplified tumors, 56% also had alterations of TOP2A, including 14.7% coamplifications, 33.3% gains and 8% deletions. 14566826 Human
top2a tumor Both HER-2 and TOP2A amplifications were significantly associated with advanced tumor stage (HER-2 p < 0.0001, TOP2A p = 0.0218), high grade (p < 0.0001 for both) and protein overexpression (p < 0.0001 for both). 14566826 Human
top2a tumors TOP2A amplification and overexpression were linked to shortened survival in muscle-invasive tumors (p = 0.0042 and 0.0077, respectively). 14566826 Human
top2a bladder cancer In summary, our data suggest that HER-2 amplifications are frequently linked to alterations of the TOP2A gene in bladder cancer. 14566826 Human
top2a tumors Excess copies of the TOP2A were also seen at the DNA level in 10 of 16 cases, and high expression of the TOP2A protein was seen in 83% of the tumors on the tissue microarray. 14673046 Human
top2a breast cancer Gene copy mapping of the ERBB2/TOP2A region in breast cancer. 15034864 Human
top2a breast cancer Amplification of at least one gene near ERBB2, topoisomerase IIalpha (TOP2A), has been shown to be clinically significant, but the prevailing patterns of gene amplification in this region of chromosome arm 17q have not been studied systematically in clini 15034864 Human
top2a breast tumor For characterizing this region, a commercial ERBB2-containing contig probe and 7 probes prepared from single overlapping BAC and P1 clones lying telomeric to ERBB2 and including TOP2A were hybridized to 77 ERBB2-amplified archival breast tumor specimens f 15034864 Human
top2a tumors Also, tumors that showed deletion of TOP2A usually showed deletion of one or more contiguous targets. 15034864 Human
top2a tumor TOP2A was amplified in 25% of all tumor specimens and was deleted in 24%, based on a deletion criterion of there being fewer than or equal to 0.75 targets per chromosome 17 centromere. 15034864 Human
top2a breast carcinomas Considering the relevance of the TOP2A gene product to anthracycline therapy and the wealth of other cancer-associated genes within the ERBB2/TOP2A region, the pattern of amplification and deletion near ERBB2 and TOP2A may have a dramatic effect on the ma 15034864 Human
top2a breast cancer TOP2A is amplified or deleted together with amplification of the closely located ERBB2/HER-2/neu oncogene in breast cancer. 10469452 Human
top2a breast tumors We characterized the copy number aberrations of TOP2A and ERBB2 in 136 primary breast tumors by FISH. 10469452 Human
top2a tumors Among the 70 primary tumors with ERBB2 amplification, amplification of TOP2A was found in 29 (41%); 30 tumors (43%) showed a physical deletion of TOP2A; and the copy number for TOP2A was not altered in 11 tumors with ERBB2 amplification (16%). 10469452 Human
top2a primary tumors Among the 70 primary tumors with ERBB2 amplification, amplification of TOP2A was found in 29 (41%); 30 tumors (43%) showed a physical deletion of TOP2A; and the copy number for TOP2A was not altered in 11 tumors with ERBB2 amplification (16%). 10469452 Human
top2a primary tumors No TOP2A gene aberrations were identified in 65 primary tumors without ERBB2 amplification. 10469452 Human
top2a primary tumors The deletion of TOP2A (seen in the MDA-361 cell line and in 31 primary tumors) was interstitial, spanning less than two megabases of DNA. 10469452 Human
top2a primary tumors Eight primary tumors with high-level ERBB2 amplification showed a new type of intratumoral heterogeneity; two different cell clones with either high-level amplification or deletion of TOP2A were found adjacent to each other in the same tumor. 10469452 Human
top2a tumor Eight primary tumors with high-level ERBB2 amplification showed a new type of intratumoral heterogeneity; two different cell clones with either high-level amplification or deletion of TOP2A were found adjacent to each other in the same tumor. 10469452 Human
top2a tumors These results indicate that amplification of the ERBB2 oncogene is followed by complex secondary genetic aberrations, which lead to amplification or deletion of the TOP2A gene in a majority of tumors. 10469452 Human
top2a cancers The protein products of these two genes are important cellular targets of several drugs widely used in the treatment of many human cancers, and a variety of mutations in TOP2A have been associated with the development of drug resistance. 9795238 Human
top2 tumor The following studies in tissue culture models have suggested that acidic pH acts like a TOP2 poison to induce TOP2-mediated DNA damage: (i) acidic pH induces TOP2-dependent DNA damage signals as evidenced by up-regulation of p53 and Ser-139 phosphorylati 12692309 Human
top2 human leukemia Cloning and sequencing of cDNA segments of human TOP2 gene encoding the 170 kDa form of human DNA topoisomerase II show that Arg486 of the enzyme has been mutated to a lysine in the enzyme from two human leukemia cell lines HL-60/AMSA and KBM-3/AMSA, whic 1311390 Human
top2a breast tumors The topoisomerase IIalpha (topoIIalpha) gene (TOP2A) is located adjacent to the HER-2 oncogene at the chromosome location 17q12-q21 and is either amplified or deleted, with equal frequency, in almost 90% of HER-2 amplified primary breast tumors. 12871052 Human
top2a cancer Topoisomerase 2 Alpha (TOP2A) which is located nearby the HER-2/neu gene is an important molecular target for several anti cancer drugs. 12647367 Human
top2a urinary bladder cancer The frequency of TOP2A amplification in urinary bladder cancer is unknown. 12647367 Human
top2a urinary bladder cancer It was the aim of this study to determine the frequency of HER-2 and TOP2A amplification in urinary bladder cancer and to evaluate the association of these amplifications with tumor phenotype. 12647367 Human
top2a tumor It was the aim of this study to determine the frequency of HER-2 and TOP2A amplification in urinary bladder cancer and to evaluate the association of these amplifications with tumor phenotype. 12647367 Human
top2a carcinomas TOP2A amplification was present in 0.7% pTa, 1.8% pT1 and 3.4% pT2-4 carcinomas (p < 0.0001). 12647367 Human
top2a tumors TOP2A was found in none of the grade 1, in 0.2% of grade 2 and 3.8% of grade 3 tumors (p < 0.0001). 12647367 Human
top2a tumors 1% of all analyzed tumors had simultaneously high level amplification of TOP2A and HER-2. 12647367 Human
top2a urinary bladder cancer [HER-2 and TOP2A gene amplification in urinary bladder cancer] 12691100 Human
top2a ovarian tumors Real-time RT-PCR analysis showed that mRNA for HER2/neu and 3 SEREX-defined antigens, TOP2A, HOXB6 and DDX5, was more abundant in ovarian tumors than most normal tissues, including normal and benign ovarian tissues, suggesting that elevated expression of 12532422 Human
top2a childhood all In conclusion, characterization of TOP2A gene status in childhood ALL at diagnosis provides useful complementary information for risk assessment. 12646941 Human
top2a glioblastomas These analyses confirmed that the transcript levels of nine of the selected genes (COL4A2, FOXM1, MGP, TOP2A, CENPF, IGFBP4, VEGFA, ADD3, and CAMK2G) differed significantly in WHO grade II astrocytomas as compared to anaplastic astrocytomas and/or gliobla 12937144 Human
top2a who grade ii astrocytomas These analyses confirmed that the transcript levels of nine of the selected genes (COL4A2, FOXM1, MGP, TOP2A, CENPF, IGFBP4, VEGFA, ADD3, and CAMK2G) differed significantly in WHO grade II astrocytomas as compared to anaplastic astrocytomas and/or gliobla 12937144 Human
top2a anaplastic astrocytomas These analyses confirmed that the transcript levels of nine of the selected genes (COL4A2, FOXM1, MGP, TOP2A, CENPF, IGFBP4, VEGFA, ADD3, and CAMK2G) differed significantly in WHO grade II astrocytomas as compared to anaplastic astrocytomas and/or gliobla 12937144 Human
top2a bladder tumor To study the amplification and expression of TOP2A and HER-2 and associations with tumor phenotype and clinical outcome in bladder cancer, a tissue microarray containing 2,317 bladder tumor samples was analyzed by FISH and immunohistochemistry. 14566826 Human
top2a breast tumours TOP2A gene is located adjacent to the HER-2 oncogene at the chromosome location 17q12-q21 and is either amplified or deleted, with equal frequency, in almost 90% of HER-2 amplified primary breast tumours. 14632727 Human
top2a breast tumours In this issue of the Cytopathology, Bofin et al. present preliminary evidence for high prevalance of TOP2A amplification and deletion not only in the HER-2 amplified breast tumours, but also in the primary breast tumours without the HER-2 amplification. 14632727 Human
top2a mpnst CONCLUSION: We have identified TOP2A as a target gene in MPNST, using a focused gene expression profiling followed by a DNA copy number evaluation and clinical validation of the encoded protein using a tissue microarray. 14673046 Human
top2a mpnst This study is the first to suggest that TOP2A expression may be a predictive factor for adverse outcome in MPNST. 14673046 NA
top2a ovarian carcinoma The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel. 14985451 Human
top2a tumor Concurrently, tumor tissue and primary cultures displayed low transcript levels of proliferation-related genes, such as, TOP2A, ANKT, RAD51, UBE2C, CENPA, RRM2, and PLK. 15260889 Human
top2a breast cancer TOP2A is frequently coamplified with c-erb-B2 and consequently might be a prognostic and/or predictive factor for breast cancer patients when anthracycline-based chemotherapy is a consideration. 15628907 Human
top2a breast carcinomas A total of 20% to 35% of breast carcinomas show amplification of the erb-B2 gene, some of which also have coamplification of the TOP2A gene. 15628907 Human
top2a breast cancer DESIGN: We developed an assay and analyzed the gene copy numbers of the erb-B2 and TOP2A genes in 8 breast cancer cell lines, 6 fresh frozen samples, and 38 paraffin-embedded breast tumor specimens by a novel real-time polymerase chain reaction (PCR) assa 15628907 Human
top2a breast tumor DESIGN: We developed an assay and analyzed the gene copy numbers of the erb-B2 and TOP2A genes in 8 breast cancer cell lines, 6 fresh frozen samples, and 38 paraffin-embedded breast tumor specimens by a novel real-time polymerase chain reaction (PCR) assa 15628907 Human
top2a invasive breast carcinoma Finally, we observed that TOP2A amplification only occurred in conjunction with erb-B2 amplification in our paraffin-embedded cases of invasive breast carcinoma and that this event was present in 5 (42%) of 12 erb-B2 amplified cases. 15628907 Human
top2a tumours The prognostic significance of amplification of four of the genes (EMS1, TOP2A, CCNE1, and ERBB2) was then evaluated, using fluorescent in situ hybridization on a tissue microarray, in a second larger 'validation' series of 232 tumours with a me 15682439 Human
top2a pancreatic cancer We sought to identify the frequency of amplification of the topoisomerase IIalpha gene (TOP2A) in pancreatic cancer and determine the usefulness of TOP2A immunolabeling in screening for TOP2A and human epidermal growth factor receptor (HER)2/neu amplifica 15762277 Human
top2a pancreatic adenocarcinoma We examined 55 pancreatic adenocarcinoma specimens for TOP2A immunolabeling and identified TOP2A protein expression in all specimens with a nuclear labeling index (NLI; positive nuclei/total nuclei x 100) of 5% to 80%. 15762277 NA
top2a pancreatic adenocarcinoma Normal pancreatic ductal epithelium, proposed to give rise to pancreatic adenocarcinoma, did not demonstrate detectable TOP2A expression. 15762277 Human
top2a pancreatic adenocarcinoma In 8 of 9 TOP2A-amplified cases, coamplification of HER2/neu was present, suggesting a potential relationship between TOP2A and HER2/neu in pancreatic adenocarcinoma. 15762277 Human
top2a pancreatic adenocarcinoma We propose that TOP2A immunolabeling be used in conjunction with a newly developed multicolor probe to screen patients with pancreatic adenocarcinoma to determine the best potential therapeutic modalities, such as TOP2A inhibitors, trastuzumab, or both. 15762277 Human
top2a breast cancer Clinical and in vitro evidence supports the concept that human epidermal growth factor receptor-2 ( HER2 ) gene amplification prediction of response to anthracycline-based chemotherapy in breast cancer is not a direct effect of HER2 overexpression, but th 15891995 Human
top2a breast cancer One hundred thirty-eight cases of breast cancer HER2 gene amplified by 2-color FISH ( HER2 /CEP17) were reevaluated with a 3-color probe set ( HER2 /CEP17/ TOP2A ) to investigate the frequency of coamplification and deletion of TOP2A . 15891995 Human
top2a breast cancer The current study demonstrates the complex interrelationship between the HER2 and TOP2A genes in breast cancer. 15891995 Human
top2a breast cancer The clinical implications of TOP2A amplification and deletion in breast cancer need to be further defined. 15891995 Human
top2a tumor If TOP2A gene dosage can be confirmed to correlate with tumor responsiveness to anthracycline-based therapy in the clinical setting, FISH testing for TOP2A status may be warranted to aid in the selection of the most appropriate therapy. 15891995 Human
topoisomerase ii alpha non-small cell lung cancer Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. 1373318 Human
topoisomerase ii alpha adenocarcinoma Southern blot analysis of DNA extracted from lung cancer cell lines detected amplification of both the topoisomerase II alpha and ERBB2 genes in the adenocarcinoma line Calu3. 1373318 Human
topoisomerase ii alpha lung cancer Southern blot analysis of DNA extracted from lung cancer cell lines detected amplification of both the topoisomerase II alpha and ERBB2 genes in the adenocarcinoma line Calu3. 1373318 Human
topoisomerase ii alpha adenocarcinoma These results indicate that topoisomerase II alpha and ERBB2 may be closely linked on chromosome 17 and coamplified during adenocarcinoma progression. 1373318 Human
topoisomerase ii alpha human tumour We have quantified the level of topoisomerase II beta mRNA in a panel of human tumour cell lines of different origin using an RNase protection assay, and compared the level to that of topoisomerase II alpha mRNA. 1333583 Human
topoisomerase ii alpha human tumor Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo. 1338275 Human
topoisomerase ii alpha breast cancer Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. 8096076 Human
topoisomerase ii alpha human primary breast cancer Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. 8096076 Human
topoisomerase ii alpha breast cancer Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. 8104440 Human
topoisomerase ii alpha tumours We show that of 50 tumours examined, the topoisomerase II alpha locus is co-amplified in 3 cases out of 6 with erbB2 amplification and that amplification can be accompanied by high expression of topoisomerase II alpha. 8104440 Human
topoisomerase ii alpha an adenocarcinoma Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. 8398710 Human
topoisomerase ii alpha lung adenocarcinoma We have analysed a lung adenocarcinoma cell line CALU3, which has co-amplified topoisomerase II alpha and ERBB2 sequences, for the structure of the amplicon and for expression of both topoisomerase II alpha and beta. 8398710 NA
topoisomerase ii alpha breast cancers The region of chromosome 17q amplified in CALU3 also includes the retinoic acid receptor alpha locus and is therefore similar to the amplicon observed in breast cancers carrying amplified topoisomerase II alpha and retinoic acid receptor sequences. 8398710 Human
topoisomerase ii alpha adenocarcinomas Thus, the CALU3 cell line is an ideal model to study the amplification and expression of topoisomerase II alpha in adenocarcinomas. 8398710 Human
topoisomerase ii alpha small-cell lung cancer Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. 8104687 Human
topoisomerase ii alpha murine leukemia Previous studies using cloned lines of Adriamycin-sensitive and -resistant P388 murine leukemia cells have suggested that a reduction in DNA topoisomerase II alpha (topo II alpha) enzyme activity and protein levels in drug-resistant cell lines (A. M. 8261398 Mouse
topoisomerase ii alpha small-cell lung cancer Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. 8306338 Human
topoisomerase ii alpha human leukemia Topoisomerase II alpha (topo II alpha) mRNA was down-regulated to a greater extent in 2 human leukemia HL-60 cell lines sensitive to PMA-induced terminal differentiation than in their non-differentiating daughter lines following exposure to PMA (Cancer Re 8166723 Human
topoisomerase ii alpha human ovarian cancer Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer. 8172796 Human
topoisomerase ii alpha ovarian tumours In the current study we have analysed ovarian tumours for expression of topoisomerase II alpha and genetic change at the topoisomerase II alpha locus on chromosome 17. 8172796 Human
topoisomerase ii alpha ovarian cancer MATERIALS AND METHODS: We have used methodology which allows the sequential extraction of protein and genomic DNA from the same biopsy sample to study the topoisomerase II alpha locus and the expression in ovarian cancer. 8172796 NA
topoisomerase ii alpha tumours Topoisomerase II alpha expression was quantified by Western blot analysis in 54 tumours. 8172796 Human
topoisomerase ii alpha ovarian tumours RESULTS: Topoisomerase II alpha expression was detected in 65% of ovarian tumours with a 16 fold range in level. 8172796 Human
topoisomerase ii alpha adenocarcinomas In adenocarcinomas, the topoisomerase II alpha gene can become amplified due to its proximity to ERBB2 on chromosome 17q. 8172796 Human
topoisomerase ii alpha ovarian tumours Of 86 ovarian tumours studied only 1 had amplification of ERBB2 and none had amplification of topoisomerase II alpha a sequences. 8172796 Human
topoisomerase ii alpha ovarian carcinomas CONCLUSIONS: Topoisomerase II alpha expression was detected in ovarian carcinomas by Western blot analysis. 8172796 Human
topoisomerase ii alpha tumours A sixteen-fold range in expression was detected with significantly higher levels of topoisomerase II alpha expression in advanced stage IV and grade III tumours. 8172796 Human
topoisomerase ii alpha solid tumours It is suggested that the carbamate analogues of amsacrine recognize a form of topoisomerase II, possibly topoisomerase II beta, the activity of which increases relative to that of topoisomerase II alpha in non-cycling cells, and might be used to devise ne 8194167 Human
topoisomerase ii alpha small-cell lung cancer Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. 8041119 Human
topoisomerase ii alpha human small cell lung carcinoma EXPERIMENTAL DESIGN: The titration assay was used to quantitate the amount of DNA topoisomerase II alpha mRNA in a human small cell lung carcinoma cell line, GLC4 and its drug-resistant sublines, GLC4/ADR and GLC4/CDDP. 8041119 Human
topoisomerase ii alpha cancer CONCLUSIONS: The DNA topoisomerase II alpha titration assay is a highly sensitive new technique to study the role of DNA topoisomerase II alpha in drug resistance and may help to identify cancer types and patients most likely to respond to DNA topoisomera 8041119 Human
topoisomerase ii alpha acute lymphoblastic leukemia (all) We found a concomitant increase in mdr1 and mrp gene expression combined with a decreased expression of topoisomerase II alpha in the course of the second relapse of an acute lymphoblastic leukemia (ALL). 7914748 Human
topoisomerase ii alpha acute myeloid leukaemia Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. 8090029 Human
topoisomerase ii alpha cll In contrast to the low or even absent topoisomerase II alpha gene expression, however, the expression of the topoisomerase II beta gene was generally high in the CLL lymphocytes exceeding the value observed in the cell line CCRF VCR 100 up to 5-fold. mdr1 7954350 Human
topoisomerase ii alpha human tumor The topoisomerase II alpha protein was phosphorylated predominantly on serine residues in the human tumor cell lines HeLa and NSCLC-3. 7961967 Human
topoisomerase ii alpha acute lymphoblastic leukemia Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. 7805045 Human
topoisomerase ii alpha childhood acute lymphoblastic leukemia The levels of expression of topoisomerase II alpha and topoisomerase II beta were investigated in six established cell lines of human childhood acute lymphoblastic leukemia (ALL) as a function of doubling time, cell cycle distribution, and of sensitivity 7805045 Human
topoisomerase ii alpha acute lymphoblastic leukaemias Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. 7873386 Human
topoisomerase ii alpha leukaemia Calculating the mean values we found: (i) a distinctly lower mdr1 gene expression in primary ALL and first relapses compared to bone marrow from healthy donors, (ii) no change in mdr1 and mrp, but a decreased topoisomerase II alpha gene expression in firs 7873386 Human
topoisomerase ii alpha human leukemia Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. 7712479 Human
topoisomerase ii alpha human leukemia Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells. 7723730 Human
topoisomerase ii alpha melanoma A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. 7727383 Human
topoisomerase ii alpha human lung cancer Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. 7743513 Human
topoisomerase ii alpha lung cancer Using a VP-16-selected lung cancer cell line, H209/V6, we have identified a third resistance mechanism which involves an aberrant subcellular location of the topoisomerase II alpha isoenzyme. 7743513 Human
topoisomerase ii alpha cancer We have shown previously that H209/V6 cells express two topoisomerase II alpha mRNAs (6.1 and 4.8 kilobases) but only a single catalytically active protein which has a M(r) of 160,000 and is located primarily in the cytoplasm (Mirski et al., Cancer Res., 7743513 Human
topoisomerase ii alpha cancer DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. 7641205 Human
topoisomerase ii alpha cancer We previously isolated etoposide/teniposide-resistant cell lines from human cancer KB cells, designated KB/VP-2 and KB/VM-4, respectively, and we found that decreased expression of topoisomerase II alpha was associated with the acquisition of etoposide/te 7641205 Human
topoisomerase ii alpha human leukemia The importance of nuclear matrix topoisomerase II alpha as a target for certain anticancer agents was evaluated in CEM human leukemia cells. 7572348 Human
topoisomerase ii alpha childhood acute lymphoblastic leukemia Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. 7564505 Human
topoisomerase ii alpha leukemia Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. 7585537 Human
topoisomerase ii alpha human breast cancer Using this antibody, together with a polyclonal antibody specific for the 170 kDa isoform of topoisomerase II, we have examined the relationship between the sensitivity of a panel of human breast cancer cell lines to different classes of topoisomerase II 8519659 Human
topoisomerase ii alpha breast cancer No relationship was found between the level of mRNA for topoisomerase II alpha or beta, and either sensitivity of breast cancer cell lines to topoisomerase II inhibitors or the level of topoisomerase II protein expression. 8519659 Human
topoisomerase ii alpha mammary carcinoma To investigate this observation, we developed a model of topoisomerase II overexpression by transfecting a full-length Chinese hamster ovary topoisomerase II alpha into EMT6 mouse mammary carcinoma. 8521401 Human
topoisomerase ii alpha superficial bladder cancer Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes. 8543398 Human
topoisomerase ii alpha superficial bladder cancer Biopsies of superficial bladder cancer were analysed to study the relationship between response to epirubicin and the expression of the human topoisomerase II alpha and beta genes. 8543398 Human
topoisomerase ii alpha acute myelogenous leukemias (aml) For investigation of relative differences in mRNA expression levels and of correlations in the expression of genes possibly involved in multidrug resistance (MDR) of acute myelogenous leukemias (AML), a complementary DNA polymerase chain reaction (cDNA-PC 8642857 Human
topoisomerase ii alpha aml Within the group of relapsed state AML a significant negative correlation between the gene expression levels of MDR1 and topoisomerase II alpha (rs= -0.5500, P<0.01, n=22) was observed. 8642857 Human
topoisomerase ii alpha human breast cancers Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. 8664122 Human
topoisomerase ii alpha tumours Moreover, the ratio of mRNA levels for topoisomerase II alpha and beta showed a stronger relationship to SPF (median raito 0.62 for tumours with SPF < 10, and 1.64 for SPF > 10; P = 0.0021, sign-rank test). 8664122 Human
topoisomerase ii alpha tumour Immunohistochemical analysis revealed that topoisomerase II beta was widely distributed ( > 90% positive tumour cells), but that topoisomerase II alpha expression was less widely expressed, with a pattern of expression similar to that of the proliferation 8664122 Human
topoisomerase ii alpha lung cancer The examination of topoisomerase II alpha content by Western blot analysis or topoisomerase II catalytic activity by decatenation of kDNA requires a large number of cells, but it is difficult to collect sufficient cells for these biochemical analyses from 8695154 Human
topoisomerase ii alpha prostate cancer Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. 8712704 Human
topoisomerase ii alpha prostate cancer By employing the prostate-specific antigen promoter (PSAP), we investigated (1) whether PSAP-driven antisense genetic constructs targeting DNA polymerase-alpha and topoisomerase II alpha (Top II alpha), designated PSAP-antipol and PSAP-antitop respectivel 8712704 Human
topoisomerase ii alpha malignant tumors However, a comparison of median values indicated a remarkable increase of expression in malignant tumors over benign or normal tissues only for topoisomerase II alpha. 8759604 Human
topoisomerase ii alpha nonsmall cell carcinoma Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. 8756364 Human
topoisomerase ii alpha nsclc In this study we compared DNA topoisomerase II alpha expression in SCLC and NSCLC by immunohistochemistry. 8756364 NA
topoisomerase ii alpha nsclc We hypothesized that the sensitivity of SCLC and relative insensitivity of NSCLC to these chemotherapeutic agents stem from different frequencies of DNA topoisomerase II alpha expression. 8756364 Human
topoisomerase ii alpha nsclc METHODS. DNA topoisomerase II alpha expression was analyzed in 17 cases of SCLC and 24 cases of NSCLC by immunohistochemistry utilizing a monoclonal antibody recognizing the alpha isoform of DNA topoisomerase II. 8756364 Human
topoisomerase ii alpha nsclc CONCLUSIONS. We conclude that DNA topoisomerase II alpha is expressed at a higher frequency in SCLC than in NSCLC, and that this expression is possibly involved in the response of SCLC to chemotherapeutic agents. 8756364 Human
topoisomerase ii alpha small-cell lung carcinoma A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4 displays decreasing DNA topoisomerase II alpha (TopoII alpha) mRNA levels with increasing resistance. 8761362 Human
topoisomerase ii alpha breast tumor Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. 8823806 Human
topoisomerase ii alpha human erythroleukemia Phorbol ester-induced down-regulation of topoisomerase II alpha mRNA in a human erythroleukemia cell line. 8831726 Human
topoisomerase ii alpha brain tumour We have investigated the possibility of overcoming the resistance of human brain tumour cells (HBT20) to etoposide by transferring the normal human topoisomerase II alpha (H-topo II) gene into these cells. 8870683 Human
topoisomerase ii alpha mouse mammary cancer Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. 8884812 Human
topoisomerase ii alpha acute myeloid leukemia (aml) A fluorescence image cytometry technique was developed to measure the effects of topotecan, a topoisomerase I inhibitor, on the nuclear expression of topoisomerase II alpha in a series of patients with refractory or relapsed acute myeloid leukemia (AML). 8914817 Human
topoisomerase ii alpha leukemia In human acute leukemia cell lines, topoisomerase II alpha expression was greatest in late S and G2 phases, but in leukemia patient samples the enzyme expression appeared to be much less cell cycle dependent. 8914817 Human
topoisomerase ii alpha acute leukemia In human acute leukemia cell lines, topoisomerase II alpha expression was greatest in late S and G2 phases, but in leukemia patient samples the enzyme expression appeared to be much less cell cycle dependent. 8914817 Human
topoisomerase ii alpha leukemia There was considerable interpatient variation in the effects of topotecan on topoisomerase II alpha expression in the leukemia patients, with a threefold increase in the median value after 48 h followed by a decline to pretreatment levels after 5 days of 8914817 Human
topoisomerase ii alpha small-cell lung carcinoma Sublines of the human small-cell lung carcinoma (SCLC) cell line GLC4 with acquired resistance to teniposide, amsacrine and mitoxantrone (GLC4/VM20x, GLC4/AM3x and GLC4/MIT60x, respectively) were derived to study the contribution of DNA topoisomerase II a 8980384 Human
topoisomerase ii alpha murine leukemia Allelic fusion of DNA topoisomerase II alpha and retinoic acid receptor alpha genes in adriamycin-resistant p388 murine leukemia revealed by fluorescence in situ hybridization. 9040785 Human
topoisomerase ii alpha human tumours Drug-resistance in cell lines and in malignant human tumours is associated with dysregulation of several genes including mdr1, MRP1, GST-pi, bcl-2, DNA topoisomerase II alpha and beta, and thymidine kinase I. mRNA expression was evaluated by quantitative 9042217 Human
topoisomerase ii alpha human tumour Drug-resistance in cell lines and in malignant human tumours is associated with dysregulation of several genes including mdr1, MRP1, GST-pi, bcl-2, DNA topoisomerase II alpha and beta, and thymidine kinase I. mRNA expression was evaluated by quantitative 9042217 Human
topoisomerase ii alpha tumor Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. 8972219 Human
topoisomerase ii alpha lung cancer Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. 8996519 Human
topoisomerase ii alpha human lung cancer PURPOSE: Topoisomerase II alpha content, topoisomerase II catalytic activity and drug sensitivities to the topoisomerase II inhibitors, doxorubicin and etoposide, were examined in a panel of 14 unselected human lung cancer cell lines in order to determine 8996519 NA
topoisomerase ii alpha nsclc The relative topoisomerase II alpha levels and relative topoisomerase II catalytic activity from SCLC cell lines (mean +/- SD 0.89 +/- 0.54 and 5.3 +/- 3.4, respectively) were slightly higher than those from NSCLC cell lines (0.78 +/- 0.56 and 4.0 +/- 2.8 8996519 Human
topoisomerase ii alpha tumours In this area of the tumours, multidrug-resistance-related genes, i.e., MDRI, MRP, GST-pi and topoisomerase II alpha were activated concomitantly with MYCN and max genes. 9033651 Human
topoisomerase ii alpha tumour Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. 9059350 Human
topoisomerase ii alpha non-hodgkin's lymphoma Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. 9059350 Human
topoisomerase ii alpha tumour AIMS: To elucidate potential mechanisms of drug resistance, levels of topoisomerase II alpha mRNA, a target for cytostatic drugs, were measured in cryopreserved tumour tissue from 36 patients with non-Hodgkin's lymphoma. 9059350 NA
topoisomerase ii alpha non-hodgkin's lymphoma AIMS: To elucidate potential mechanisms of drug resistance, levels of topoisomerase II alpha mRNA, a target for cytostatic drugs, were measured in cryopreserved tumour tissue from 36 patients with non-Hodgkin's lymphoma. 9059350 NA
topoisomerase ii alpha low-grade lymphomas RESULTS: Levels of topoisomerase II alpha mRNA correlated strongly with the Ki-67 labelling index and were higher in high grade than in low grade lymphomas. 9059350 Human
topoisomerase ii alpha high-grade lymphoma Patients in complete clinical remission of high grade lymphoma had a higher Ki-67 labelling index and tended to have higher topoisomerase II alpha mRNA levels. 9059350 Human
topoisomerase ii alpha non-hodgkin's lymphomas Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas. 9071722 Human
topoisomerase ii alpha soft-tissue tumors A multivariate study. In 132 soft-tissue sarcomas and 52 benign soft-tissue tumors, cellular proliferation was examined by immunohistochemistry using monoclonal antibodies Ki-S11 (Ki-67 antigen) and Ki-S1 (topoisomerase II alpha) and by flow cytometric an 9176393 Human
topoisomerase ii alpha soft-tissue sarcomas A multivariate study. In 132 soft-tissue sarcomas and 52 benign soft-tissue tumors, cellular proliferation was examined by immunohistochemistry using monoclonal antibodies Ki-S11 (Ki-67 antigen) and Ki-S1 (topoisomerase II alpha) and by flow cytometric an 9176393 Human
topoisomerase ii alpha tumor Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines. 9268990 Human
topoisomerase ii alpha human tumor Previous studies have shown that human tumor cell lines can express more than one topoisomerase II alpha isoform through alternative splicing. 9268990 Human
topoisomerase ii alpha tumor Thus, although T-lineage tumor cell lines examined (CEM, Jurkat, and H9) displayed altered topoisomerase II alpha isoforms, normal T cells expressed only a full-length copy of the gene. 9268990 Human
topoisomerase ii alpha adrenocortical neoplasms DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. 9310953 Human
topoisomerase ii alpha carcinomas DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. 9310953 Human
topoisomerase ii alpha adenomas DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. 9310953 Human
topoisomerase ii alpha glioma Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha. 9330528 Human
topoisomerase ii alpha leukemia Identifying transcriptional regulators of DNA topoisomerase II alpha (topo II alpha) is essential to decipher the mechanisms underlying leukemia cell resistance to topo II-directed antitumor drugs. 9379678 Human
topoisomerase ii alpha human renal-cell carcinoma Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide. 9393588 Human
topoisomerase ii alpha human tumor DNA topoisomerase II alpha is the intracellular target for several important chemotherapeutic agents, and drug-resistant human tumor cell lines have been described in which deletions in the C-proximal region of this enzyme are associated with its cytoplas 9434641 Human
topoisomerase ii alpha acute leukemia Expression of DNA topoisomerase II alpha and multidrug resistance p-glycoprotein in acute leukemia. 9439046 Human
topoisomerase ii alpha acute leukemia METHODS: We used immunohistochemical method to determine the expressions of both topoisomerase II alpha (topo II alpha) and p-glycoprotein (gp-170) in bone marrow biopsy specimens from 68 cases of acute leukemia. 9439046 NA
topoisomerase ii alpha cancer Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines. 9473741 Human
topoisomerase ii alpha germ cell tumor Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. 9504690 Human
topoisomerase ii alpha epithelial ovarian carcinoma Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. 9504690 Human
topoisomerase ii alpha ovarian cancer DNA topoisomerase II alpha (topo II alpha) is associated with active cell proliferation and is a target for chemotherapeutic agents administered to patients with ovarian cancer. 9504690 Human
topoisomerase ii alpha non-small-cell lung cancer MATERIALS AND METHODS: Because several authors showed that p53 mutated gene was able to induce mdr1 overexpression, we evaluated in 51 non small cell lung cancer samples, already tested for p53 mutations, the expression of mdr1, mrp, DNA topoisomerase II 9713494 NA
topoisomerase ii alpha non-small cell lung cancer Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer. 9765623 Human
topoisomerase ii alpha human colorectal carcinomas Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. 10597187 Human
topoisomerase ii alpha carcinoma In this study, we asked whether YB-1 expression is enhanced in human colorectral carcinoma and if it is associated with the expression of target genes such as MDR-1, DNA topoisomerase II alpha and PCNA. 10597187 NA
topoisomerase ii alpha human colorectal carcinomas YB-1, DNA topoisomerase II alpha, PCNA and MDR-1 expression were assessed by Western blotting, Northern blotting and immunohistochemistry in 26 human colorectal carcinomas. 10597187 Human
topoisomerase ii alpha human colon cancer We also found that a transient co-transfection with a DNA topoisomerase II alpha promoter-luciferase plasmid and an antisense YB-1 expression construct resulted in a significant reduction of the promoter activity in KM12C human colon cancer cells. 10597187 Human
topoisomerase ii alpha recurrent meningiomas [Immunohistochemical evaluation of intracranial recurrent meningiomas: correlation of topoisomerase II alpha expression and cell proliferative potential] Most of meningiomas belong to benign tumor. 10654298 Human
topoisomerase ii alpha squamous cell carcinomas of the head and neck Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. 10769652 Human
topoisomerase ii alpha cancers of the head and neck The aim of the present study was to examine topoisomerase II alpha (topo II alpha) expression in cancers of the head and neck and to establish a correlation with clinicopathological parameters and survival. 10769652 Human
topoisomerase ii alpha tumor Topoisomerase II alpha expression was correlated with age, gender, stage, site of the disease, tumor differentiation, response to chemotherapy, disease-free survival and overall survival. 10769652 Human
topoisomerase ii alpha tumors Topoisomerase II alpha expression was significantly higher in tumors of low and moderate differentiation versus tumors of high differentiation (P = 0.00001). 10769652 Human
topoisomerase ii alpha tumors In conclusion, topoisomerase II alpha is highly expressed in histological specimens of the majority of patients with head and neck cancers; mainly, it is related to a significant degree to low and moderately differentiated tumors versus highly differentia 10769652 Human
topoisomerase ii alpha head-and-neck cancers In conclusion, topoisomerase II alpha is highly expressed in histological specimens of the majority of patients with head and neck cancers; mainly, it is related to a significant degree to low and moderately differentiated tumors versus highly differentia 10769652 Human
topoisomerase ii alpha lung tumor Simultaneous quantitation of topoisomerase II alpha and beta isoform mRNAs in lung tumor cells and normal and malignant lung tissue. 10879730 Human
topoisomerase ii alpha epithelial neoplasms of the ovary Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. 10907174 Human
topoisomerase ii alpha non-small cell lung cancer PURPOSE: The purpose of this study was to assess the prognostic value of the expression of p53 and bcl-2, the apoptotic index and the expression of topoisomerase II alpha in patients with inoperable non-small cell lung cancer (NSCLC) treated with high dos 10927139 NA
topoisomerase ii alpha nsclc PURPOSE: The purpose of this study was to assess the prognostic value of the expression of p53 and bcl-2, the apoptotic index and the expression of topoisomerase II alpha in patients with inoperable non-small cell lung cancer (NSCLC) treated with high dos 10927139 NA
topoisomerase ii alpha glioma [Correlation between DNA topoisomerase II alpha expression and sensitivity to etoposide in human glioma cell lines] The expression of topoisomerase II alpha (Topo II alpha) was investigated in six human glioma cell lines as a function of doubling time, ce 10969596 Human
topoisomerase ii alpha papillary carcinoma Formalin-fixed paraffin-embedded tissues from 61 randomly selected patients with thyroid disease, including 29 cases of Graves' disease with papillary architectural features and 32 cases of papillary carcinoma, were analyzed for expression of p27, Ki 11007042 Human
topoisomerase ii alpha rb In this report, we evaluated several molecular markers (topoisomerase II alpha, E-cadherin, HER-2/neu, and retinoblastoma (RB) gene protein) that have not been previously studied in PHEOs. 11127918 Human
topoisomerase ii alpha retinoblastoma In this report, we evaluated several molecular markers (topoisomerase II alpha, E-cadherin, HER-2/neu, and retinoblastoma (RB) gene protein) that have not been previously studied in PHEOs. 11127918 Human
topoisomerase ii alpha rb Gross (tumor size, weight, local extension, cyst formation, hemorrhage, necrosis), microscopic (pleomorphism, hyaline globules, intranuclear inclusion, mitotic count, capsular and vascular invasion, ganglionic/neuronal differentiation), and immunohistoche 11127918 Human
topoisomerase ii alpha necrosis Gross (tumor size, weight, local extension, cyst formation, hemorrhage, necrosis), microscopic (pleomorphism, hyaline globules, intranuclear inclusion, mitotic count, capsular and vascular invasion, ganglionic/neuronal differentiation), and immunohistoche 11127918 Human
topoisomerase ii alpha cyst Gross (tumor size, weight, local extension, cyst formation, hemorrhage, necrosis), microscopic (pleomorphism, hyaline globules, intranuclear inclusion, mitotic count, capsular and vascular invasion, ganglionic/neuronal differentiation), and immunohistoche 11127918 Human
topoisomerase ii alpha rb We studied the immunohistochemical expression of topoisomerase II alpha, MIB-1, p53, RB gene protein product, E-cadherin, and HER-2/neu in a series of adrenal and extra-adrenal PHEOs. 11127918 NA
topoisomerase ii alpha rb Overexpression of topoisomerase II alpha and MIB-1 and loss of RB protein product were more common in malignant lesions, whereas p53, E-cadherin, and HER-2/neu do not seem to have diagnostic utility in the prediction of biologic behavior in these neoplasm 11127918 Human
topoisomerase ii alpha neoplasms Overexpression of topoisomerase II alpha and MIB-1 and loss of RB protein product were more common in malignant lesions, whereas p53, E-cadherin, and HER-2/neu do not seem to have diagnostic utility in the prediction of biologic behavior in these neoplasm 11127918 Human
topoisomerase ii alpha laryngeal carcinomas Expression of topoisomerase II alpha, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation. 11200824 Human
topoisomerase ii alpha laryngeal cancers AIM: To determine whether topoisomerase II alpha (topoIIa) expression is an additional prognostic marker for less advanced stage laryngeal cancers first treated without surgery. 11200824 Human
topoisomerase ii alpha leukemia Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines. 11205246 Human
topoisomerase ii alpha secondary glioblastomas In 27 primary and 17 secondary glioblastomas and their astrocytic precursor tumors, we studied the immunohistochemical expression profile of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), lung resistance-related protein (LRP), metal 11263502 Human
topoisomerase ii alpha tumors In 27 primary and 17 secondary glioblastomas and their astrocytic precursor tumors, we studied the immunohistochemical expression profile of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), lung resistance-related protein (LRP), metal 11263502 Human
topoisomerase ii alpha glioblastomas Glial tumor cells in all glioblastomas showed constant up-regulation of LRP, MRP, and topoisomerase II alpha. 11263502 Human
topoisomerase ii alpha glial tumor Glial tumor cells in all glioblastomas showed constant up-regulation of LRP, MRP, and topoisomerase II alpha. 11263502 Human
topoisomerase ii alpha glioma Inhibition of topoisomerase II alpha subunit de novo synthesis by specific antisense oligonucleotides suppresses human glioma T98G cell growth. 10344108 Human
topoisomerase ii alpha node-negative breast carcinomas Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. 10365096 Human
topoisomerase ii alpha carcinomas of the breast The prognostic impact of p53, c-erbB-2, and topoisomerase II alpha expression was investigated in relation to standard prognostic factors for carcinomas of the breast and to the tumour cell growth fraction. 10365096 Human
topoisomerase ii alpha tumour The prognostic impact of p53, c-erbB-2, and topoisomerase II alpha expression was investigated in relation to standard prognostic factors for carcinomas of the breast and to the tumour cell growth fraction. 10365096 Human
topoisomerase ii alpha infiltrating ductal carcinomas Paraffin-embedded specimens of 356 node-negative infiltrating ductal carcinomas were stained immunohistochemically using a polyclonal antiserum to c-erbB-2, and the monoclonal antibodies DO-1 (p53), Ki-S4 (topoisomerase II alpha), and Ki-S5 (Ki-67). 10365096 Human
topoisomerase ii alpha large tumour Both p53 and c-erbB-2 were significantly associated with high tumour grade, large tumour size, DNA aneuploidy, lack of steroid hormone receptors, young age, and increased topoisomerase II alpha and Ki-67 expression levels. 10365096 Human
topoisomerase ii alpha tumour Both p53 and c-erbB-2 were significantly associated with high tumour grade, large tumour size, DNA aneuploidy, lack of steroid hormone receptors, young age, and increased topoisomerase II alpha and Ki-67 expression levels. 10365096 Human
topoisomerase ii alpha tumour Topoisomerase II alpha and Ki-67 scores closely paralleled each other, indicating that both reflect the proliferative activity of tumour cells. 10365096 Human
topoisomerase ii alpha tumour Multivariate analysis with inclusion of all covariates selected tumour size and proliferation (topoisomerase II alpha and Ki-67) indices as independent predictors of survival in all three models. 10365096 Human
topoisomerase ii alpha breast cancer It is concluded that the proliferative activity, as assessed by topoisomerase II alpha or Ki-67 immunostaining, is the most useful indicator of breast cancer prognosis, except for tumour size. 10365096 Human
topoisomerase ii alpha tumour It is concluded that the proliferative activity, as assessed by topoisomerase II alpha or Ki-67 immunostaining, is the most useful indicator of breast cancer prognosis, except for tumour size. 10365096 Human
topoisomerase ii alpha tumour Among these 6 genes, 3 transcription factors as well as the topoisomerase II alpha and the mitosis inhibitor WEE1Hu gene were significantly suppressed in the tumour cell lines. 10446455 Human
topoisomerase ii alpha breast cancer Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. 10469452 Human
topoisomerase ii alpha esophageal squamous-cell carcinoma Topoisomerase II alpha expression in esophageal squamous cell carcinoma. 10470130 Human
topoisomerase ii alpha childhood acute lymphoblastic leukaemia Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome. 11271785 Human
topoisomerase ii alpha breast cancer Breast cancer specimens were also evaluated in a blinded fashion for tumor grade and immunoreactivity to estrogen and progesterone receptors, p53, her2-neu, and topoisomerase II alpha. 11173152 Human
topoisomerase ii alpha tumor Breast cancer specimens were also evaluated in a blinded fashion for tumor grade and immunoreactivity to estrogen and progesterone receptors, p53, her2-neu, and topoisomerase II alpha. 11173152 Human
topoisomerase ii alpha breast tumors Breast tumors from patients who received radiation therapy for Hodgkin's disease displayed greater nuclear pleomorphism (p < 0.02), and an increase in topoisomerase II alpha expression (p < 0.05) vs. the control population. 11173152 Human
topoisomerase ii alpha wilms' tumors Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors. 11299842 Human
topoisomerase ii alpha wilms' tumor The objective of this study was to analyze the immunohistochemical distribution of two markers of cytostatic drug resistance, e.g. DNA topoisomerase II alpha (Topo II alpha) and glutathione S-transferase-pi (GST-pi) in 23 Wilms' tumor patients who ha 11299842 Human
topoisomerase ii alpha bladder carcinoma Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma. 11304849 Human
topoisomerase ii alpha carcinomas BACKGROUND: The purpose of this study was to investigate the correlation between topoisomerase II alpha (Topo II alpha) expression and the chemosensitivity to Topo II-targeting drugs in gynaecological carcinomas. 11396183 Human
topoisomerase ii alpha pituitary adenomas Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas. 11478267 Human
topoisomerase ii alpha pituitary adenomas The immunohistological expression of cyclin D1, cyclin D3, and Topoisomerase II alpha was studied in a collection of 60 clinically inactive surgically removed pituitary adenomas of the follicle-stimulating hormone/luteinizing hormone (FSH/LH) cell complex 11478267 Human
topoisomerase ii alpha adenomas The immunohistological expression of cyclin D1, cyclin D3, and Topoisomerase II alpha was studied in a collection of 60 clinically inactive surgically removed pituitary adenomas of the follicle-stimulating hormone/luteinizing hormone (FSH/LH) cell complex 11478267 Human
topoisomerase ii alpha adenoma Topoisomerase II alpha was demonstrated in the nuclei of 42 adenomas (70%) with no significant differences discernible between the three adenoma subtypes. 11478267 Human
topoisomerase ii alpha adenomas Topoisomerase II alpha was demonstrated in the nuclei of 42 adenomas (70%) with no significant differences discernible between the three adenoma subtypes. 11478267 Human
topoisomerase ii alpha tumor There was no significant correlation to the time of development of tumor symptoms, but a correlation of Topoisomerase II alpha with cyclin D3 and the proliferation marker Ki-67 (Mib1). 11478267 Human
topoisomerase ii alpha adrenocortical neoplasms Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. 11556748 Human
topoisomerase ii alpha oesophageal squamous cell carcinoma The prognostic significance of proliferative activity, apoptosis and expression of DNA topoisomerase II alpha in multimodally-treated oesophageal squamous cell carcinoma. 11848536 Human
topoisomerase ii alpha oesophageal squamous cell carcinoma The present study retrospectively examined the correlation between the outcome of patients with locally advanced oesophageal squamous cell carcinoma (cT3-4 cN0-1 cM0) after multimodal treatment (radiochemotherapy +/- surgical resection) and the parameters 11848536 Human
topoisomerase ii alpha tumour The present study retrospectively examined the correlation between the outcome of patients with locally advanced oesophageal squamous cell carcinoma (cT3-4 cN0-1 cM0) after multimodal treatment (radiochemotherapy +/- surgical resection) and the parameters 11848536 Human
topoisomerase ii alpha meningiomas Topoisomerase II alpha as a reliable proliferation marker in meningiomas. 11958416 Human
topoisomerase ii alpha acute myeloid leukemia (aml) To determine whether the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytoplasmic 5'-nucleotidase (5NT), cytidine deaminase (CDD), topoisomerase I (TOPO I) and topoisomerase II alpha (TOPO II) are involved in clin 12008078 Human
topoisomerase ii alpha ovarian cancer [Expression of c-erbB-2 and topoisomerase II alpha in relation to chemoresistance in ovarian cancer] In the present study, we examined die role of c-erbB-2 for chemoresistance in ovarian cancer. 12070798 Human
topoisomerase ii alpha germ-cell tumour DNA topoisomerase II alpha is the target for etoposide, which is currently used regularly in germ cell tumour treatment. 12237772 Human
topoisomerase ii alpha embryonal carcinoma Strong topoisomerase II alpha expression was found in embryonal carcinoma. 12237772 Human
topoisomerase ii alpha tumors No correlation with the presence of ITC before or after chemotherapy could be found, yet pat. with topoisomerase II alpha neg. tumors showed a trend to reduced disease free survival. 12506757 Human
topoisomerase ii alpha cancer We have previously shown that the cells become resistant to topoisomerase II alpha (topo II alpha) targeted cancer chemotherapeutic drug such as etoposide (VP-16) when GRP78 is up-regulated by various means. 12504087 Human
topoisomerase ii alpha synovial sarcomas Fifty-four surgically resected synovial sarcomas were examined immunohistochemically for nuclear expression of YB-1 and intrinsic expression of P-glycoprotein, MRP1, MRP2, and topoisomerase II alpha, and the findings were compared with clinicopathological 12533839 Human
topoisomerase ii alpha tumors All tumors were additionally stained for the proliferation markers Ki-67 and DNA topoisomerase II alpha (TopoIIalpha). 12640680 Human
topoisomerase ii alpha glioblastoma MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma. 12760291 Human
topoisomerase ii alpha glioblastomas We studied the MIB-1 labeling index (LI) and DNA topoisomerase II alpha LI of glioblastomas from 34 patients who lived for more than 2 years after diagnosis and of glioblastomas from 34 age- and sex-matched control patients who died within 2 years of diag 12760291 Human
topoisomerase ii alpha glioblastomas Our study showed that both MIB-1 and topoisomerase II alpha could help predict long-term survival of patients with glioblastomas. 12760291 Human
topoisomerase ii alpha small cell lung cancer (sclc) Bisdioxopiperazine-resistant small cell lung cancer (SCLC) OC-NYH/Y165S and Chinese hamster ovary (CHO) CHO/159-1 cells having functional Y49F and Y165S mutations in the topoisomerase II alpha isoform were both resistant to F 11782. 12906927 others
topoisomerase ii alpha pancreas cancer The protein products of 14 genes encompassing a variety of functional classes, such as tumor suppressor genes (p53, Smad4/Dpc4), oncogenes (beta-catenin), cell cycle antigens (p16, cyclin D1), proliferation antigens (Ki-67, topoisomerase II alpha), and ep 13679454 Human
topoisomerase ii alpha panin The protein products of 14 genes encompassing a variety of functional classes, such as tumor suppressor genes (p53, Smad4/Dpc4), oncogenes (beta-catenin), cell cycle antigens (p16, cyclin D1), proliferation antigens (Ki-67, topoisomerase II alpha), and ep 13679454 Human
topoisomerase ii alpha breast cancer Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? 14499010 Human
topoisomerase ii alpha tumors We evaluated the clinicopathologic features of Merkel cell carcinomas and examined the expression of the cell cycle regulatory markers p27 and S-phase kinase-associated protein 2 (Skp2) and the proliferation markers Ki-67 and DNA topoisomerase II alpha (t 14586067 Human
topoisomerase ii alpha merkel-cell carcinomas We evaluated the clinicopathologic features of Merkel cell carcinomas and examined the expression of the cell cycle regulatory markers p27 and S-phase kinase-associated protein 2 (Skp2) and the proliferation markers Ki-67 and DNA topoisomerase II alpha (t 14586067 Human
topoisomerase ii alpha tumor CONCLUSION: Topoisomerase II alpha is also the target of many antineoplastic drugs and it has been proposed that its expression in tumor cells correlates with chemosensitivity. 14666704 Human
topoisomerase ii alpha breast cancer Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 14728934 Human
topoisomerase ii alpha breast cancer The aim of this study was to evaluate the predictive value of five different biological factors in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy: (1) tumour grade scored according to the Elston-Ellis classification, (2) 14728934 Human
topoisomerase ii alpha tumour The aim of this study was to evaluate the predictive value of five different biological factors in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy: (1) tumour grade scored according to the Elston-Ellis classification, (2) 14728934 Human
topoisomerase ii alpha papillary thyroid carcinomas Topoisomerase II alpha and telomerase expression in papillary thyroid carcinomas. 14736527 Human
topoisomerase ii alpha tumour BACKGROUND: Altered topoisomerase II alpha (Topo II alpha) expression and telomerase activity (TA) reflect tumour cell growth and malignant transformation. 14736527 Human
topoisomerase ii alpha breast tumor Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. 14978790 Human
topoisomerase ii alpha breast cancer Topoisomerase II alpha, encoded by TOP2A, is a direct molecular target of anthracycline drug action and is potentially useful as a predictive marker of response to anthracycline therapy for breast cancer. 14978790 Human
topoisomerase ii alpha breast tumors In this study, we examined whether TOP2A gene amplification is an appropriate marker for identifying breast tumors expressing high levels of topoisomerase II alpha. 14978790 NA
topoisomerase ii alpha breast tumors We determined topoisomerase II alpha protein expression by immunohistochemistry in 81 human breast tumors in relation to HER2 and TOP2A gene copy numbers analyzed by fluorescence in situ hybridization, histologic grade, cell proliferation fraction measure 14978790 Human
topoisomerase ii alpha breast tumors The results showed no correlation between TOP2A gene copy number and topoisomerase II alpha protein expression levels in breast tumors, in contrast to the analogous situation for HER2 gene amplification and HER2 immunohistochemistry. 14978790 Human
topoisomerase ii alpha acute lymphoblastic leukemia Impact of Topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia. 15068901 Human
topoisomerase ii alpha oral squamous-cell carcinomas Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. 15188142 Human
topoisomerase ii alpha tumour Immunohistochemical staining for various glial and neuronal markers, proliferative markers (MIB-1, Topoisomerase II alpha PCNA) and tumour suppressor gene protein expression of p53 and retinoblastoma (Rb) were performed. 15203749 Human
topoisomerase ii alpha retinoblastoma Immunohistochemical staining for various glial and neuronal markers, proliferative markers (MIB-1, Topoisomerase II alpha PCNA) and tumour suppressor gene protein expression of p53 and retinoblastoma (Rb) were performed. 15203749 Human
topoisomerase ii alpha ovarian carcinoma Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. 15385105 Human
topoisomerase ii alpha ovarian carcinomas OBJECTIVE: This study investigated the expression of vascular endothelial growth factor (VEGF) and topoisomerase II alpha (TPII alpha) in a cohort of serous ovarian carcinomas by immunohistochemistry with regard to outcome and clinicopathologic variables. 15385105 NA
topoisomerase ii alpha myeloma We have previously found that myeloma and leukemic cells in transition from low-density log phase conditions to high-density plateau phase conditions export substantial amounts of endogenous topoisomerase II alpha from the nucleus to the cytoplasm. 15173319 Human
topoisomerase ii alpha breast cancer Although the present results cannot have an impact on current practice, they allow us to formulate the hypothesis that HER-2 positive breast cancer is a heterogeneous disease with regard to sensitivity to anthracyclines and taxanes, and that this might be 15567936 Human
topoisomerase ii alpha metastatic gastric cancer Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. 15640503 Human
topoisomerase ii alpha metastatic gastric cancer OBJECTIVE: This retrospective study aimed to ascertain the expression of erbB2 in relation to topoisomerase II alpha (T2 alpha) and thymidylate synthase (TS) markers in 30 consecutive metastatic gastric cancer patients with a specimen available for study. 15640503 NA
topoisomerase ii alpha tumor The drug-resistance genes were investigated in tumor tissues by RT-PCR with the specific primers for MDR-1, MRP-1, MRP-2, MXR-1, MGMT, GST-pei, and topoisomerase II alpha. 15700834 Human
topoisomerase ii alpha leukemia The present findings are consistent with the hypothesis that topoisomerase II alpha plays a role in the initiation of specific types of leukemia that are induced by benzene and its metabolites. 15833037 Human
topoisomerase ii alpha tumor We analyzed nine markers including tumor suppressor gene (14-3-3 sigma), proliferation marker (topoisomerase II alpha), epithelial markers (prostate stem cell antigen, mesothelin and cytokeratin 19), stromal markers (fascin, hsp47 and fibronectin), and ga 15696124 Human
topoisomerase ii alpha solid-pseudopapillary tumors Expression of topoisomerase II alpha is not seen in solid pseudopapillary tumors and undifferentiated carcinomas with osteoclastic-like giant cells but is focally seen in pancreatoblastomas (50%) and acinar cell carcinomas (85%). 15696124 Human
topoisomerase ii alpha acinar cell carcinomas Expression of topoisomerase II alpha is not seen in solid pseudopapillary tumors and undifferentiated carcinomas with osteoclastic-like giant cells but is focally seen in pancreatoblastomas (50%) and acinar cell carcinomas (85%). 15696124 Human
topoisomerase ii alpha undifferentiated carcinomas Expression of topoisomerase II alpha is not seen in solid pseudopapillary tumors and undifferentiated carcinomas with osteoclastic-like giant cells but is focally seen in pancreatoblastomas (50%) and acinar cell carcinomas (85%). 15696124 Human
topoisomerase ii alpha invasive carcinomas Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables. 16097435 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.